✓ Translated by DotMD AI Clinical Council Source: Liver international : official journal of the International Association for the Study of the Liver • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #30721572 ↗

Randomized Controlled Trial: Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease (N = 15)

Original Paper Title: “Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 15
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Liraglutide was effective for decreasing weight, hepatic steatosis and hepatocellular apoptosis in obese adults with NAFLD, but benefits were not sustained after discontinuation, in contrast with lifestyle modification. Continuing the exercise learned in the structured programme contributed to the maintenance of liver fat reduction.
  • Study Design & Sample: Randomized Controlled Trial published in Liver international : official journal of the International Association for the Study of the Liver (N = 15 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Liver international : official journal of the International Association for the Study of the Liver (2019), this randomized controlled trial evaluating 15 human participants investigated: We compared the effects of weight loss induced with the glucagon-like peptide-1 agonist liraglutide, with that of lifestyle modification, followed by weight maintenance after discontinuing intervention, in obese adults with non-alcoholic fatty liver disease (NAFLD). Key clinical takeaway: Liraglutide was effective for decreasing weight, hepatic steatosis and hepatocellular apoptosis in obese adults with NAFLD, but benefits were not sustained after discontinuation, in...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Liver international : official journal of the International Association for the Study of the Liver, 2019-05-15; N = 15; Rigor 82/100): Liraglutide was effective for decreasing weight, hepatic steatosis and hepatocellular apoptosis in obese adults with NAFLD, but benefits were not sustained after discontinuation, in contrast with lifestyle modification. Continuing the exercise learned in the structured programme contributed to the maintenance of liver fat reduction.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: liraglutide → Rx: healthy-back-institute-rub-on-relief-analgesic → Condition: alcohol → Condition: biliary-colic → Condition: pancreatitis-chronic →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 30721572: Randomized Controlled Trial: Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease (N = 15)

3 of 3 Free Questions Remaining